The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy …
GW Sledge, M Toi, P Neven, J Sohn, K Inoue… - JAMA …, 2020 - jamanetwork.com
Importance Statistically significant overall survival (OS) benefits of CDK4 and CDK6
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2
(formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of
menopausal status after prior endocrine therapy (ET) has not yet been demonstrated.
Objective To compare the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant
on OS at the prespecified interim of MONARCH 2 (338 events) in patients with HR-positive …
inhibitors in combination with fulvestrant for hormone receptor (HR)–positive, ERBB2
(formerly HER2)-negative advanced breast cancer (ABC) in patients regardless of
menopausal status after prior endocrine therapy (ET) has not yet been demonstrated.
Objective To compare the effect of abemaciclib plus fulvestrant vs placebo plus fulvestrant
on OS at the prespecified interim of MONARCH 2 (338 events) in patients with HR-positive …